AIM Rule 26

The following information is disclosed in accordance with AIM Rule 26.

Summit Therapeutics is a biotechnology company focussed on the development of new mechanism antibiotics.  Click on the following link for a description of our business

Registered name: Summit Therapeutics plc
Country of incorporation: England & Wales
Main country of operation: United Kingdom
Registered address: 136a Eastern Avenue Milton Park Abingdon Oxfordshire OX14 4SB United Kingdom
Company Secretary: Melissa Strange, FCCA
Registered number: 05197494
VAT number: 876331407

 

The Company’s current articles of association can be viewed here:

Articles of Association

Summit’s shares are traded on the AIM market of the London Stock Exchange and Nasdaq Global Market.  Click here  for more information about number of securities in issue and, insofar as the company is aware, the percentage of AIM securities not in public hands, together with the identity and percentage of significant shareholders.

Click here for access to the Company’s Annual and Interim Reports.

Click here to view all regulatory news notifications made by the Company.

The Company’s Admission Document to AIM, a market of the London Stock Exchange is available:

IPO Admission Document

Please note this document was issued more than twelve years ago and is accordingly substantially
out of date. For more accurate and up-to-date information, please refer to other sections of this website, the latest Annual Report, our filings with the US Securities & Exchange Commission, recent regulatory announcements and other such information
sources on the web.

All circulars and notice of meetings that have been sent to shareholders are available below:

2019 Notice of Annual General Meeting
Circular and Notice of General Meeting (Jan 4, 2019)
2018 Notice of Annual General Meeting
2017 Notice of Annual General Meeting
2016 Notice of Annual General Meeting
2015 Notice of Annual General Meeting
2014 Notice of Annual General Meeting

Poll Results for General Meeting (Jan 4, 2019)

Votes For % of Shares Voted Votes Against % of Shares Voted Votes Withheld
Resolution 1:
To authorise the Directors to allot and issue new ordinary shares
39,723,809 99.02% 392,303 0.98% 17,175
Resolution 2:
To dis-apply pre-emption rights
39,707,430 98.98% 410,903 1.02% 14,954
Resolution 3:
To approve the waiver of Rule 9 of the Takeover Code
39,797,345 99.21% 315,488 0.79% 20,454
A “Withheld” vote is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution

We are committed to maintaining a high standard of corporate governance. Click here for further details about our approach.

Summit Therapeutics plc is subject to the UK City Code on Takeovers and Mergers.

Click here for details of the Company’s advisers.

This section of the website, and the information that can be accessed from this page, was last updated to comply with AIM Rule 26 on:
15 February 2019.